Articles tagged with “nvidia”

Examine why enterprise AI demands custom infrastructure, compute, and data pipelines over generic chat apps, featuring the Eli Lilly supercomputer case study.

Nvidia paid $20B for Groq's assets (2.9x its $6.9B valuation). Analysis of the deal structure, LPU technology, and antitrust implications — updated April 2026 with the Warren-Blumenthal Senate inquiry.

NVIDIA H100: $25K-$40K. H200: ~$31K ($315K/8-GPU). B200: $30K-$50K. B300: $300K-$350K. Full 2026 buy vs. cloud rental cost breakdown.

Oracle's $300B, 5-year cloud deal with OpenAI: 4.5 GW/year of compute, the live Abilene campus, and Oracle's $523B contract backlog as of 2026.

Explore the Nvidia Blackwell vs Hopper GPU architectures. Key technical differences in tensor cores (FP4/FP6), memory, MLPerf benchmarks, and the road to Rubin — updated for 2026.

Explore a data-driven comparison of the AI boom and the dot-com bubble. We analyze key metrics like valuations, profitability, and VC funding — updated with 2026 data including NVIDIA's $4.3T market cap, OpenAI's $730B valuation, and $258.7B in AI VC funding.

Analysis of the $90B OpenAI-AMD strategic partnership for 6GW of MI450 GPUs, including stock warrants, MI450 specs (CDNA 5, 2nm, HBM4), and OpenAI's 33GW multi-vendor compute strategy

How AI leaders like Amodei, Hassabis, and Huang are accelerating drug discovery, genomics, and life science breakthroughs—compressing decades into years. Updated January 2026 with AlphaFold 3, Claude for Life Sciences, NVIDIA Evo 2, and $3B+ pharma partnerships.

A comprehensive analysis of how pharmaceutical and biotech companies are leveraging NVIDIA's latest H100 and Blackwell GPUs to accelerate drug discovery, protein structure prediction, and AI-driven research, with detailed case studies from leading companies.